Navigation Links
Financial Assistance Now Available for People with Acute Lymphoblastic Leukemia
Date:6/27/2011

component of induction therapy for ALL, one dose of Oncaspar® achieved similar levels of asparagine depletion as six to nine doses of native L-asparaginase.

Oncaspar® allows patients to gain the full benefits of asparaginase therapy with less frequent dosing schedule compared with native L-asparaginase (nonPEGylated form).  Through the process of pegylation, the half-life of L-asparaginase is significantly increased and the L-asparaginase activity is sustained.  Oncaspar® is a registered trademark of Defiante Farmaceutica S.A.

Important Oncaspar® Safety Information:
Oncaspar® is contraindicated in patients with a history of serious allergic reactions to Oncaspar®, and in patients with a history of serious thrombosis, pancreatitis or serious hemorrhagic events with prior L-asparaginase therapy.

Oncaspar® should be discontinued in the case of anaphylaxis or serious allergic reactions, thrombosis or pancreatitis.  Glucose intolerance, in some cases irreversible, can occur. Coagulopathy can occur.  Perform appropriate monitoring.  The most common adverse reactions with Oncaspar® (> or = 2 percent) are allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, central nervous system (CNS) thrombosis, coagulopathy, hyperbilirubinemia and elevated transaminases.  

About Sigma-Tau Pharmaceuticals, Inc.:
Sigma-Tau Pharmaceuticals, Inc. is a U.S.-based, wholly owned subsidiary of the Sigma-Tau Group, and is dedicated solely to the global development and commercialization of medicines for patients with rare diseases.  Sigma-Tau Pharmaceuticals, Inc. is based in Gaithersburg, Md.  Since 1989, the company's products have been focused on rare diseases, including kidney disease, certain genetic disorders and cancers.  With more than 7,000 identified rare diseases that affect approximately 25 million patients in the
'/>"/>

SOURCE Sigma-Tau Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ULURU Inc. Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor
2. New 340B Integrity Provisions in the Affordable Care Act Could Result in Substantial Financial Penalties
3. TPI Discusses Non-Cash Non-Operational Financial Impact from Warrants
4. Thoratec Announces Resignation of Chief Financial Officer
5. TetraLogic Appoints Jonathan B. Lloyd Jones as Chief Financial Officer and Vice President Corporate Development
6. China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results
7. Reportlinker Adds Global Top 10 Pharmaceutical Companies: Industry, Financial and SWOT Analysis
8. Within3 Adds Chief Financial Officer
9. Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011
10. China Nepstar Chain Drugstore Reports First Quarter 2011 Financial Results
11. Neuland Labs Reports Financial Results for Fiscal Year 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Calif. and VIENNA, Va. ... innovative in-home care provider that operates in ... a leading provider of remote caregiving technology. Alta will ... and existing client receiving homecare services. Logo ... this technology is the key to providing the kind ...
(Date:11/21/2014)... Fla. , Nov. 21, 2014   Rock ... announced that the Company is scheduled to present at ... San Francisco, CA on January 12-14, 2015. ... Chairman and CEO of Rock Creek Pharmaceuticals, will present ... molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. Dr. ...
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... instruments and consumables for the medical, research, and veterinary ... veterinary and research markets in the United ... stock purchase agreement to acquire 100% of QCR & ... based distribution organization. The transaction closed on November ...
Breaking Medicine Technology:Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4
... 16, 2007 - Amgen,(Nasdaq:AMGN) today presented the results ... the,efficacy and safety of Aranesp(R) (darbepoetin alfa) for ... not receiving,chemotherapy or radiotherapy ("the 103 study"). Aranesp ... EMEA in these patients. These,results were presented in ...
... WIRE)--Apr 16, 2007 - Arsenic, a naturally,occurring element, ... years, and even now remains a venerable constituent ... to the efforts of investigators supported,by grants from ... Walls," an arsenic derivative is being,utilized in therapy ...
Cached Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells 2Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells 3
(Date:11/24/2014)... November 24, 2014 Volpara Solutions ... 1.2 at the 100th Annual Meeting of the ... 5, 2014 (RSNA Booth 1752 – South Hall). ... VolparaAnalytics and the rest of its innovative suite ... VolparaDoseRT, which enable personalized measurements of volumetric density, ...
(Date:11/24/2014)... Recently, SweetDressy.com, a well-known dress supplier and leader ... 2014 Evening Dresses. All these fresh items are offered ... manager, the special offer is valid until Dec. 20, ... has been working well in the fashion industry for ... Their new dresses may be the best products for ...
(Date:11/24/2014)... SafeHandles™ announced that they will be featured in ... airing via Discovery Channel. Dates and show times TBA. ... replaceable, and affordable germ protective device. This segment will ... adhesives to promote hand hygiene in high traffic and ... is the desire to make a positive impact in ...
(Date:11/23/2014)... The clinical trial report, "Aspergillosis Global ... the Aspergillosis clinical trial scenario. This report provides ... trials on Aspergillosis. It includes an overview of ... per the site of trial conduction across the ... disease clinical trials by their phase, trial status, ...
(Date:11/23/2014)... November 23, 2014 Pro Ace Care, a ... it will now be providing an 8 year warranty on ... water tank installations went up due to the impending winter ... its customers of the premium service that the company provides. ... year warranty on John Wood and Bradford hot water tanks. ...
Breaking Medicine News(10 mins):Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2
... popularity of weight training has grown over the past ... Injury Research and Policy of The Research Institute at ... injuries from weight training has increased as well. The ... were treated in U.S. hospital emergency departments between 1990 ...
... ... independent inspections and audits that enable AIB’s worldwide foodservice clients to lower business ... ... North America,s largest providers of third-party food safety audits , recently selected ...
... comment on risks from scans , TUESDAY, March 30 (HealthDay ... much radiation will get a public airing this week as ... meetings on what should be done to increase the safety ... seeking ideas to get manufacturers of the devices used for ...
... ... Can Benefit From A Posture Brace ( www.posturenow.com ) , ... (PRWEB) March 30, 2010 -- Within minutes ... the blogosphere was abuzz with comments about Chad Ochocinco’s poor posture. , , ,Chad’s ...
... ... Approach to Application Whitelisting by Verifying Insecure Software and Applications to Help Customers Improve ... ... Lumension , a global leader in endpoint management and security, today announced it has ...
... ... elder care law, released this statement concerning a March/April AARP article entitled "Love is (Not) ... for 44 years was forced to divorce in order to protect their remaining savings to ... off the mark , ...
Cached Medicine News:Health News:New national study examines weight training-related injuries 2Health News:New national study examines weight training-related injuries 3Health News:AIB International to Implement MetricStream for Compliance and Safety Audits 2Health News:AIB International to Implement MetricStream for Compliance and Safety Audits 3Health News:AIB International to Implement MetricStream for Compliance and Safety Audits 4Health News:Too Much Radiation? The FDA Wants to Know 2Health News:Too Much Radiation? The FDA Wants to Know 3Health News:Dancing With The Slouching Stars: Chad Ochocinco Fumbles When It Comes To Posture 2Health News:Lumension Partners With Citrix To Advance Desktop Virtualization Security 2Health News:Lumension Partners With Citrix To Advance Desktop Virtualization Security 3Health News:Lumension Partners With Citrix To Advance Desktop Virtualization Security 4Health News:Lumension Partners With Citrix To Advance Desktop Virtualization Security 5Health News:Prominent National Elder Law Attorney Disputes AARP Article Recommending Divorce to Afford Health Care 2Health News:Prominent National Elder Law Attorney Disputes AARP Article Recommending Divorce to Afford Health Care 3
... Volu-Sol's New Methylene Blue, ... to use. This stain ... does not require any counter-staining. ... in three different sizes, 30 ...
... in methanol for faster, more complete ... smears. Our special manufacturing process yields ... elements producing unequaled definition of cytoplasmic ... brilliance in the resulting smear. Used ...
... Volu-Sol's Stat Stain is ideal for stat, ... stain blood smears (10-15 seconds) and bone ... generates finely dispersed stain particles which yield ... eliminates many of the steps involved in ...
... single-solution staining, Hema-Quik II for ... into stain solution for five ... deionized water for five to ... time by dipping quickly in ...
Medicine Products: